Venkatesh Kartik K, Lurie Mark N, Mayer Kenneth H
Department of Community Health, Division of Infectious Diseases, Department of Medicine, Alpert Medical School, Brown University/Miriam Hospital, RI, USA.
Future Virol. 2010 Jul;5(4):405-415. doi: 10.2217/fvl.10.38.
As the number of HIV infections continues to surpass treatment capacity, new HIV prevention strategies are imperative. Beyond individual clinical benefits, by rendering an individual less infectious, expanding access to highly active antiretroviral therapy (HAART) could also have a larger public health impact of curbing new HIV infections. Recent guidelines have moved towards initiating HAART at higher CD4 cell counts, thus increasing the number of individuals in need of treatment. A new treatment strategy is wanting that can simultaneously curb the epidemic and provide necessary treatment to those most in need. A recent debate has centered on whether an expansion of free and universal treatment, regardless of CD4 cell count, could be a means of HIV prevention. In light of the growing access to HAART in resource-limited settings and increasing evidence suggesting the clinical and prevention benefits of initiating treatment at higher CD4 cell counts, it is conceivable that, in the future, HAART will be an integral part of both individual-level clinical treatment programs as well as public health-based HIV prevention interventions.
随着艾滋病毒感染人数持续超过治疗能力,新的艾滋病毒预防策略势在必行。除了对个体的临床益处外,通过降低个体的传染性,扩大高效抗逆转录病毒疗法(HAART)的可及性还可能对遏制新的艾滋病毒感染产生更大的公共卫生影响。最近的指南倾向于在更高的CD4细胞计数时启动HAART,从而增加了需要治疗的人数。人们期待一种新的治疗策略,它能够同时遏制疫情,并为最需要的人提供必要的治疗。最近的一场辩论集中在,无论CD4细胞计数如何,扩大免费和普及治疗是否可能成为一种艾滋病毒预防手段。鉴于在资源有限的环境中获得HAART的机会不断增加,以及越来越多的证据表明在更高的CD4细胞计数时开始治疗具有临床和预防益处,可以想象,未来HAART将成为个体层面临床治疗方案以及基于公共卫生的艾滋病毒预防干预措施的一个组成部分。